Earnings Sentiment

Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.

Please consider a small donation if you think this website provides you with relevant information  

    

Sentiment Distribution

   

Earnings Call Transcript Word Cloud

     

Bullish Statements during Earnings call

Statement
The awareness has been enhanced due to principal factors the following positive results from the CCL study of clinical data that was presented by Ethos
Also, the combination of data, KOLs speaking positively about our product and allowing vet acceptance of Spryng in dogs and cats with the following events that have been happening
We have recently witnessed a strong movement of positive awareness by small animal veterinary doctors of our product Spryng
Our first one of the year in terms of multiple -- trade shows was the veterinary medical expo in Orlando mid-January where we had five veterinary doctors that were speakers mentioning the Spryng product, which was a very nice surprise that drew very good attendance and audience into our booth
This year, they were familiar with it and new vets that were using it and hearing really good things about and wanted to learn more and we were able to convert a lot of those into orders
That's a very powerful way of really getting the word out to the small animal doctors
Finally, we plan to increase our social media focus by highlighting our clinical study results and positive outcomes from the use of Spryng
And then this evening at VOS, Veterinary Orthopedic Societies Conference on HEPS, we expect to see another very good type presentation by the clinician
The final results of the cranial cruciate disease study provided by Ethos indicated significant improvement in 39 dogs injected with Spryng
It is our position that this clinical trial demonstrates that Spryng is a reasonable non-invasive alternative for patients with cranio crucial ligament disease when patients and/or owner factors preclude surgical intervention
She is a professor at Washington State University Veterinary School, and she basically did a pure review article in the today's veterinary practice July issue of 2023, which she indicated that Spryng should be looked at its first use product, as well as also a good choice as an alternative for dogs that cannot take NSAT, which is about 5% of the population in the United States out of the 83 million dogs
Such a library will assist our sales team to gain veterinarian acceptance this Spryng
The favorable results found in this first cohort of dogs of this study will be presented at the Veterinary Orthopedic Society Conference today on February 12, 2024
The acquisition of clinical data proving the safety and efficacy of Spryng in a multitude of indications is incredibly important to PetVivo
Again, thank you for joining our call today.
So that gives us the top two distributors, which gives a lot of confirmation of what they see this product potential is as we move forward
Bob Folkes Thank you, John, and good afternoon, everyone
       

Bearish Statements during earnings call

Statement
   

Please consider a small donation if you think this website provides you with relevant information